Memo Therapeutics raises €22.5M Series C round
2 November 2023· Zurich, Switzerland· biotech, drug_discovery, antibody_therapeutics, b2b, deep_science
The proceeds will be used to complete U.S. Phase II clinical development of its best- and first-in-class antibody, AntiBKV, intended to neutralize BK polyomavirus (BKV) infection in kidney transplant recipients, and to prepare manufacturing of the drug for Phase III. Memo Therapeutics AG will also use the funding to advance its existing antibody pipeline.
Investors
LeadPureos Bioventures
Also participating
Schroders CapitalredalpineSwisscantoVerve VenturesVesalius BiocapitalAdjuvant CapitalGF GroupFresenius Medical Care Ventures
About Memo Therapeutics
Stage
Series C
Headquarters
Zurich, Switzerland
Founded
2012
Team Size
21–50
Sectors
biotechdrug_discoveryantibody_therapeuticsb2bdeep_science